MCID: THY025
MIFTS: 58

Thymus Cancer

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thymus Cancer

MalaCards integrated aliases for Thymus Cancer:

Name: Thymus Cancer 12 43 15
Thymic Carcinoma 12 76 59 55 15 73
Malignant Thymoma 12 59
Thymus Neoplasms 44 73
Malignant Neoplasm of Thymus 73
Neoplasm of Thymus 12
Thymoma, Malignant 12
Thymoma, Familial 73
Thymic Neoplasm 12
Thymoma, Type C 73
Thymus Neoplasm 76
Thymic Tumor 12

Characteristics:

Orphanet epidemiological data:

59
thymic carcinoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: any age;

Classifications:



Summaries for Thymus Cancer

MedlinePlus : 43 The thymus is a small organ in your upper chest, under your breastbone. Before birth and during childhood, the thymus helps the body make a type of white blood cell. These cells help protect you from infections. Cancer of the thymus is rare. You are more likely to get it if you have other diseases such as myasthenia gravis, lupus or rheumatoid arthritis. Sometimes there are no symptoms. Other times, thymus cancer can cause A cough that doesn't go away Chest pain Trouble breathing Doctors use a physical exam, imaging tests, and a biopsy to diagnose thymus cancer. The most common treatment is surgery to remove the tumor. Other options include radiation therapy, chemotherapy, and hormone therapy. NIH: National Cancer Institute

MalaCards based summary : Thymus Cancer, also known as thymic carcinoma, is related to lymphoepithelioma-like thymic carcinoma and thymoma. An important gene associated with Thymus Cancer is CD5 (CD5 Molecule), and among its related pathways/superpathways are Hematopoietic cell lineage and Central carbon metabolism in cancer. The drugs Cisplatin and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include thymus, testes and lung, and related phenotypes are hyperhidrosis and fatigue

Disease Ontology : 12 A thymus cancer that derives from epithelial cells. The tumor cells in a thymic carcinoma look very different from the normal cells of the thymus, grow more quickly, and have usually spread to other parts of the body when the cancer is found.

Wikipedia : 76 Thymic carcinoma is a rare type of thymus gland cancer. It usually spreads, has a high risk of... more...

Related Diseases for Thymus Cancer

Diseases related to Thymus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 312)
# Related Disease Score Top Affiliating Genes
1 lymphoepithelioma-like thymic carcinoma 33.6 CD274 CD5 KIT KRT5
2 thymoma 30.2 AMPH CALB2 CD5 DNTT DPYSL5 KIT
3 ectopic thymus 30.2 CD5 SYP
4 spindle cell thymoma 30.1 CD5 MUC1
5 thymic epithelial tumor 30.0 CD5 KIT
6 benign mesothelioma 30.0 KRT5 KRT7
7 thymus lipoma 29.9 CD5 KRT7 SYP
8 large cell carcinoma 29.9 KRT5 KRT7 NKX2-1 SYP
9 mucinous adenocarcinoma 29.9 KRT7 MUC1 NKX2-1
10 papillary thymic adenocarcinoma 29.8 CALB2 CD5
11 papillary carcinoma 29.7 KRT7 MUC1 NKX2-1 PAX8
12 small cell cancer of the lung 29.6 KIT KRT7 NKX2-1 SYP TP53
13 adenoid cystic carcinoma 29.5 KIT KRT5 KRT7 MUC1 TP53
14 thymus adenocarcinoma 11.5
15 epithelial malignant thymoma 11.4
16 immunodeficiency with thymoma 11.3
17 thymus adenosquamous carcinoma 11.2
18 malignant type ab thymoma 11.1
19 malignant type a thymoma 11.1
20 invasive malignant thymoma 11.1
21 thymus squamous cell carcinoma 11.1
22 noninvasive malignant thymoma 11.1
23 cutaneous ganglioneuroma 10.4 KIT SYP
24 ovarian germ cell cancer 10.3 KRT7 NKX2-1
25 intratubular embryonal carcinoma 10.3 KIT KRT7
26 ovarian germ cell teratoma 10.3 KRT7 NKX2-1
27 lung acinar adenocarcinoma 10.3 KRT7 NKX2-1
28 mucinous adenofibroma 10.3 KRT7 SYP
29 breast lymphoma 10.3 CD5 SMUG1
30 gastrointestinal neuroendocrine tumor 10.3 SMUG1 SYP
31 partial motor epilepsy 10.3 SMUG1 SYP
32 gallbladder small cell carcinoma 10.3 SMUG1 SYP
33 chordoid meningioma 10.3 MUC1 SYP
34 sinonasal undifferentiated carcinoma 10.3 MUC1 SYP
35 papillary tumor of the pineal region 10.3 MUC1 SYP
36 parachordoma 10.3 KRT7 MUC1
37 secretory meningioma 10.3 KRT7 MUC1
38 large cell acanthoma 10.3 KRT5 KRT7
39 ovarian carcinosarcoma 10.3 CD274 SYP
40 athyreosis 10.3 NKX2-1 PAX8
41 water-clear cell adenoma 10.3 PAX8 SYP
42 renal pelvis adenocarcinoma 10.3 KRT7 PAX8
43 ovary neuroendocrine neoplasm 10.3 KRT7 SYP
44 atypical follicular adenoma 10.3 SYP TP53
45 neuroendocrine tumor 10.3 KRT7 NKX2-1 SYP
46 vulvar intraepithelial neoplasia 10.3 KRT7 TP53
47 protoplasmic astrocytoma 10.3 SMUG1 TP53
48 prostate small cell carcinoma 10.3 KIT NKX2-1 SYP
49 small cell carcinoma of the bladder 10.2 KRT7 NKX2-1 SYP
50 pulmonary sclerosing hemangioma 10.2 KRT7 NKX2-1 SYP

Graphical network of the top 20 diseases related to Thymus Cancer:



Diseases related to Thymus Cancer

Symptoms & Phenotypes for Thymus Cancer

Human phenotypes related to Thymus Cancer:

59 32 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000975
2 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
3 dyspnea 59 32 frequent (33%) Frequent (79-30%) HP:0002094
4 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
5 palpebral edema 59 32 frequent (33%) Frequent (79-30%) HP:0100540
6 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
7 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
8 mediastinal lymphadenopathy 59 32 frequent (33%) Very frequent (99-80%) HP:0100721
9 fatigable weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0003473
10 diaphragmatic paralysis 59 32 frequent (33%) Frequent (79-30%) HP:0006597
11 neoplasm of the thymus 59 32 hallmark (90%) Very frequent (99-80%) HP:0100521
12 ptosis 32 occasional (7.5%) HP:0000508
13 dysphagia 32 occasional (7.5%) HP:0002015
14 increased intracranial pressure 32 occasional (7.5%) HP:0002516
15 immunodeficiency 32 frequent (33%) HP:0002721
16 abnormal bleeding 32 occasional (7.5%) HP:0001892
17 edema 59 Frequent (79-30%)
18 autoimmunity 32 occasional (7.5%) HP:0002960
19 neuroendocrine neoplasm 32 occasional (7.5%) HP:0100634
20 pericarditis 32 occasional (7.5%) HP:0001701
21 headache 32 occasional (7.5%) HP:0002315
22 cardiac arrest 32 occasional (7.5%) HP:0001695
23 language impairment 32 occasional (7.5%) HP:0002463
24 dysgammaglobulinemia 32 frequent (33%) HP:0002961
25 abnormality of the vena cava 59 Frequent (79-30%)
26 abnormal vena cava morphology 32 frequent (33%) HP:0005345

MGI Mouse Phenotypes related to Thymus Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.03 AMPH CALB2 CD274 CNTNAP2 DPYSL5 GTF2I
2 nervous system MP:0003631 9.93 AMPH CALB2 CD5 CNTNAP2 DPYSL5 GTF2I
3 no phenotypic analysis MP:0003012 9.61 CD274 CD5 GTF2I KIT KRT5 NKX2-1
4 normal MP:0002873 9.28 CALB2 CD5 DNTT GTF2I KIT NKX2-1

Drugs & Therapeutics for Thymus Cancer

Drugs for Thymus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
3
Bevacizumab Approved, Investigational Phase 2 216974-75-3
4
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
5
leucovorin Approved Phase 2,Phase 1 58-05-9 6006 143
6
Belinostat Approved, Investigational Phase 2,Phase 1 866323-14-0
7
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 6055-19-2, 50-18-0 2907
8
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
9
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
10
Ramucirumab Approved, Investigational Phase 2 947687-13-0
11
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
12
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
13
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5330286 5005498
14
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
16
Lapatinib Approved March 2007, Investigational Phase 2 388082-78-8, 231277-92-2 208908 9941095
17 Amrubicin Investigational Phase 2 110267-81-7
18
Saracatinib Investigational Phase 2 379231-04-6
19
Doxil Approved June 1999 Phase 1, Phase 2 31703
20 Antimitotic Agents Phase 2
21 Angiogenesis Inhibitors Phase 2
22
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
23 Angiogenesis Modulating Agents Phase 2
24 Protein Kinase Inhibitors Phase 2
25 Insulin, Globin Zinc Phase 2
26 insulin Phase 2
27 Mitogens Phase 2
28 Vitamin B Complex Phase 2,Phase 1
29 Vitamin B9 Phase 2,Phase 1
30 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
31 Folic Acid Antagonists Phase 2,Phase 1
32 Folate Phase 2,Phase 1
33 Histone Deacetylase Inhibitors Phase 2,Phase 1
34 Immunologic Factors Phase 2,Phase 1
35 Alkylating Agents Phase 1, Phase 2
36 Antirheumatic Agents Phase 1, Phase 2
37 Antineoplastic Agents, Alkylating Phase 1, Phase 2
38 Immunosuppressive Agents Phase 1, Phase 2
39 Antibodies Phase 2
40 Immunoglobulins Phase 2
41 Antineoplastic Agents, Phytogenic Phase 2
42 Antibodies, Monoclonal Phase 2
43 Albumin-Bound Paclitaxel Phase 2
44 Topoisomerase Inhibitors Phase 1, Phase 2
45 Anti-Bacterial Agents Phase 1, Phase 2
46 Antibiotics, Antitubercular Phase 1, Phase 2
47
Celecoxib Approved, Investigational Phase 1 169590-42-5 2662
48 Analgesics, Non-Narcotic Phase 1
49 Cyclooxygenase 2 Inhibitors Phase 1
50 Anti-Inflammatory Agents, Non-Steroidal Phase 1

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
2 A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
3 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
4 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
5 Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Completed NCT00589290 Phase 2 Belinostat (PDX101)
6 Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity Completed NCT01163552 Phase 2
7 Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery Recruiting NCT03694002 Phase 2 Carboplatin;Paclitaxel
8 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting NCT01306045 Phase 2 AZD6244;MK-2206;Lapatinib;Erlotinib;Sunitinib
9 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Active, not recruiting NCT01621568 Phase 2 Sunitinib
10 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Active, not recruiting NCT01364727 Phase 2 Amrubicin
11 Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Active, not recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
12 A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor Not yet recruiting NCT03219554 Phase 2 Palbociclib
13 Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Suspended NCT03463460 Phase 2 Sunitinib Malate
14 Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer Terminated NCT00718809 Phase 2 saracatinib
15 A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Terminated NCT01100944 Phase 1, Phase 2 PXD101with cisplatin+doxorubicin+cyclophosphamide
16 Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Completed NCT01143545 Phase 1 Celecoxib;cyclophosphamide
17 Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03295227 Phase 1 Pembrolizumab
18 Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Recruiting NCT03023319 Phase 1 Bosutinib;Pemetrexed
19 Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies Active, not recruiting NCT01165658 Phase 1
20 Genetic Evaluation of Families With Endocrine Cancers Completed NCT01794676
21 Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors Completed NCT02233842
22 B-Receptor Signaling in Cardiomyopathy Completed NCT01135849
23 Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors Recruiting NCT02146170
24 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
25 Molecular Analysis of Thoracic Malignancies Enrolling by invitation NCT01385722

Search NIH Clinical Center for Thymus Cancer

Cochrane evidence based reviews: thymus neoplasms

Genetic Tests for Thymus Cancer

Anatomical Context for Thymus Cancer

MalaCards organs/tissues related to Thymus Cancer:

41
Thymus, Testes, Lung, Bone, Thyroid, Prostate, Myeloid

Publications for Thymus Cancer

Articles related to Thymus Cancer:

(show top 50) (show all 484)
# Title Authors Year
1
Concurrent thymic carcinoma and middle lobe syndrome. ( 29600097 )
2018
2
Thymoma and thymic carcinoma associated with multilocular thymic cyst: a clinicopathologic analysis of 18 cases. ( 29945642 )
2018
3
Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. ( 29702286 )
2018
4
Spontaneous remission in large-vessel vasculitis: Takayasu arteritis and paraneoplastic disorder associated with thymic carcinoma. ( 29974801 )
2018
5
A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma. ( 30121390 )
2018
6
Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma. ( 30411854 )
2018
7
Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma. ( 30429036 )
2018
8
Systemic treatments for thymoma and thymic carcinoma: A systematic review. ( 30527189 )
2018
9
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. ( 29240542 )
2018
10
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. ( 30033090 )
2018
11
A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma. ( 29467945 )
2018
12
Response to Nivolumab as Salvage Therapy in a Patient with Thymic Carcinoma. ( 29472056 )
2018
13
A Whole-Tumor Histogram Analysis of Apparent Diffusion Coefficient Maps for Differentiating Thymic Carcinoma from Lymphoma. ( 29520195 )
2018
14
A Nomogram Predicting Recurrence and Guiding Adjuvant Radiation for Thymic Carcinoma After Resection. ( 29530769 )
2018
15
Radiographic Predictors of Resectability in Thymic Carcinoma. ( 29534953 )
2018
16
Incidental Detection of Basaloid Thymic Carcinoma With 68Ga-PSMA-11 PET/CT in a Patient With Recurrent Prostate Cancer. ( 29550202 )
2018
17
Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study. ( 29567820 )
2018
18
Thymic carcinoma - a rare case report. ( 29785165 )
2018
19
Apatinib treatment in extensive metastatic advanced thymic carcinoma. ( 29921401 )
2018
20
Robot-assisted en bloc anterior mediastinal mass excision with pericardium and adjacent lung for locally advanced thymic carcinoma. ( 29963404 )
2018
21
Surgery Resection of a Massive Thymic Carcinoma during Urgent Coronary Artery Bypass Grafting. ( 29983810 )
2018
22
Mutation Ensemble for Response to Programmed Cell Death 1 Inhibition in Thymic Carcinoma. ( 30049379 )
2018
23
Fever of unknown origin caused by intrathyroidal thymic carcinoma. ( 30099866 )
2018
24
Low incidence of and mortality from a second malignancy after resection of thymic carcinoma. ( 30137401 )
2018
25
Outcomes of patients undergoing surgery for thymic carcinoma: a single-center experience. ( 30174874 )
2018
26
Utility of monoclonal PAX8 antibody for distinguishing intrathyroid thymic carcinoma from follicular cell-derived thyroid carcinoma. ( 30210064 )
2018
27
Metastatic Thymic Carcinoma with Long Survival After Treatment with Sunitinib. ( 30237943 )
2018
28
Survival outcomes after minimally invasive thymectomy for early-stage thymic carcinoma. ( 30430264 )
2018
29
L-Type Amino Acid Transporter 1 Immunoreactivity as a Possible Diagnostic and Prognostic Marker of Thymic Carcinoma. ( 30449824 )
2018
30
Ectopic cervical well differentiated thymic carcinoma: report of a diagnostically challenging rare case. ( 30477879 )
2018
31
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression. ( 30483099 )
2018
32
Mutation analysis of the EGFR gene and its downstream signaling pathway in thymic carcinoma patients from a Chinese Han population. ( 27731926 )
2018
33
Leser-Trélat Sign Secondary to Thymic Carcinoma. ( 29103671 )
2018
34
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. ( 29395863 )
2018
35
Undifferentiated thymic carcinoma with intracranial metastasis in a two-year-old. ( 29411634 )
2018
36
Diffuse Alveolar Hemorrhage Induced by Irinotecan for a Patient with Metastatic Thymic Carcinoma: A Case Report and Literature Review. ( 28674360 )
2017
37
Multicentric reticulohistiocytosis associated with thymic carcinoma. ( 28633354 )
2017
38
Correction: Long term oncological outcome of thymoma and thymic carcinoma - an analysis of 235 cases from a single institution. ( 28931090 )
2017
39
Rare Case of Spinal Cord Compression as Initial Presentation of Thymic Carcinoma. ( 29147447 )
2017
40
High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma. ( 28550415 )
2017
41
A rare highly aggressive tumour: lymphoepithelioma-like thymic carcinoma. ( 28942409 )
2017
42
Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma. ( 27791295 )
2017
43
Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets. ( 27844328 )
2017
44
An unusual combined thymic carcinoma composed of squamous cell carcinoma and type AB thymoma: a rare case report. ( 28095872 )
2017
45
The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma. ( 28126540 )
2017
46
Long term oncological outcome of thymoma and thymic carcinoma - an analysis of 235 cases from a single institution. ( 28632791 )
2017
47
Prospective Study of Stereotactic Body Radiation Therapy for Thymoma and Thymic Carcinoma: Therapeutic Effect and Toxicity Assessment. ( 29051511 )
2017
48
Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group. ( 27876674 )
2017
49
Complete Resection of Masaoka Stage IVb Thymic Carcinoma After Chemoradiotherapy. ( 28007273 )
2017
50
A Rare Tumor with a Very Rare Initial Presentation: Thymic Carcinoma as Bone Marrow Metastasis. ( 28116199 )
2017

Variations for Thymus Cancer

Cosmic variations for Thymus Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44380 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 14
2 COSM14140 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1081C>T p.R361C 18:51065548-51065548 14
3 COSM6191487 PREX2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.107G>T p.R36L 8:67952501-67952501 14
4 COSM6191489 NOTCH2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.3359G>A p.C1120Y 1:119937445-119937445 14
5 COSM2006821 KMT2D thymus,NS,thymic carcinoma,undifferentiated carcinoma c.11824C>T p.R3942W 12:49032071-49032071 14
6 COSM133763 KIT thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1657T>A p.Y553N 4:54727425-54727425 14
7 COSM6191682 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2921C>T p.A974V 23:45078488-45078488 14
8 COSM6196604 IL7R thymus,NS,thymic carcinoma,undifferentiated carcinoma c.537+1G>T p.? 5:35871214-35871214 14
9 COSM6191486 FAT1 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12706A>G p.K4236E 4:186596834-186596834 14

Expression for Thymus Cancer

Search GEO for disease gene expression data for Thymus Cancer.

Pathways for Thymus Cancer

Pathways related to Thymus Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.12 CD5 DNTT KIT
2 10.61 KIT PIK3R2 TP53

GO Terms for Thymus Cancer

Biological processes related to Thymus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.62 MUC1 TP53

Molecular functions related to Thymus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.55 AMPH CD274 CD5 CNTNAP2 DNTT DPYSL5

Sources for Thymus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....